Innocan Pharma INNPF
OTC INNPF
$1.29 +0.00 (+0.00%)
At close: Nov 12, 2026 · 4:00 PM EST

Innocan Pharma (INNPF) Cash from Financing Activities (2024 - 2025)

Updated

Innocan Pharma (INNPF) reported Cash from Financing Activities of -$3,000 for the quarter ended Sep 30, 2025, compared with $859,000 a year earlier.

Analysis

Innocan Pharma (INNPF) Cash from Financing Activities (2024 - 2025) Analysis & Trends

Over the twelve months ended Sep 30, 2025, Innocan Pharma's Cash from Financing Activities came in at $2.01 million; for the year ended Dec 31, 2023, it was $2.92 million.

  • The figure for the quarter ended Sep 30, 2025 ranks as the lowest quarterly Cash from Financing Activities since the quarter ended Jun 30, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -7.22 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn -8.53 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 6.82 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -2.43 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 6.63 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -4.39 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -1.53 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -2.51 Bn
10 Innocan Pharma 5.78 Mn 1.73 Mn 4.43 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -3,000.00
Jun 30, 2025 153,000.00
Mar 31, 2025 996,000.00
Sep 30, 2024 859,000.00
Jun 30, 2024 -5,000.00
Mar 31, 2024 1.45 Mn
API Access

Innocan Pharma Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=INNPF&period=max&api_key=YOUR_API_KEY